Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Prostate Cancer

    Houston, TX

    Search
    Prostate Cancer
    Houston, TX
    Show Map
    Map View
    Houston, TX
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      173 Prostate Cancer Trials near Houston, TX

      Power is an online platform that helps thousands of Prostate Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      AZD8186 + Docetaxel for Advanced Cancer

      Houston, Texas
      This trial tests a new drug (AZD8186) combined with chemotherapy (docetaxel) in patients with advanced solid tumors with specific genetic mutations. The new drug aims to block enzymes needed for cancer growth, while the chemotherapy helps kill or stop the spread of cancer cells. AZD8186 has shown enhanced efficacy when combined with other treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:HER2 Positive, Brain Metastases, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      23 Participants Needed

      JANX007 for Prostate Cancer

      Houston, Texas
      This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Organ Transplant, Cardiovascular Disease, Infection, Others

      272 Participants Needed

      Dixon MRI for Prostate Cancer

      Houston, Texas
      This trial studies the use of magnetic resonance imaging (MRI) with Dixon based imaging sequences in detecting prostate cancer. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. Researchers hope to learn if using a modified MRI scan technique with Dixon based imaging sequencing will help to produce better images of prostate cancer than the standard of care MRI scan technique.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Hormone Ablation, Radiation Therapy, Metal Implants, Others

      65 Participants Needed

      PRL-02 Injection for Prostate Cancer

      Houston, Texas
      This trial tests a muscle injection called PRL-02 for patients with advanced prostate cancer. It aims to slowly release the medication to help manage the disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Disease, Others
      Must Be Taking:GnRH Therapy

      174 Participants Needed

      CC-94676 for Metastatic Castration-Resistant Prostate Cancer

      Houston, Texas
      This trial is testing a new drug called CC-94676 to see if it is safe and effective for men with advanced prostate cancer that continues to grow despite hormone-lowering treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, Venous Thromboembolism, Others
      Must Be Taking:Androgen Deprivation Therapy

      250 Participants Needed

      AMG 509 for Prostate Cancer

      Houston, Texas
      This trial is testing a new drug called AMG 509 in adults to see if it is safe and to find the best dose. The study will monitor how people react to different doses.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Small Cell Carcinoma, CNS Metastases, Others
      Must Be Taking:GnRH Agonist/antagonist

      479 Participants Needed

      PF-06821497 for Small Cell Lung Cancer

      Houston, Texas
      This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Hypersensitivity, Gastrointestinal Disease, Others
      Must Be Taking:Abiraterone, Enzalutamide

      433 Participants Needed

      JNJ-56021927 + Abiraterone for Prostate Cancer

      Houston, Texas
      The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Small Cell Carcinoma, Others
      Must Not Be Taking:Seizure Threshold, PSA Reducers

      57 Participants Needed

      225Ac-PSMA-Trillium for Advanced Prostate Cancer

      Houston, Texas
      Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below the bladder) that has spread to other parts of the body. This type of prostate cancer does not respond to hormone treatment used to lower the level of testosterone, a male sex hormone, to prevent cancer from growing. The study treatment 225Ac-PSMA-Trillium, also called BAY3563254, is under development to treat advanced metastatic castration-resistant prostate cancer. It works by binding to PSMA and giving off radiation that can damage cancer cells and stop them from growing. The main purpose of this first-in-human study is to learn: * How safe is BAY3563254 in participants. * What is the recommended dose of BAY3563254 that is safe and works well that will be further tested in Part 2 of the study. * How well does BAY3563254 work in participants. To answer this, the researchers will look at: * The number and severity of medical problems including serious medical problems that participants experience after taking BAY3563254 * The number of dose-limiting toxicities (DLT) at each dose level. A DLT is a medical problem caused by a drug that is too severe to continue the use of that specific dose. * The number of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective response rate (ORR)) * The number of participants who have a decrease in the levels of PSA\* by at least 50% in their blood (also known as PSA50). PSA is a protein made by the prostate gland. High levels of PSA may indicate the presence of prostate cancer. * Participants' best response to treatment based on their PSA levels (also known as the best overall PSA response). The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose of BAY3563254 for use in the second part of the study. For this, each participant will receive one of different increasing amounts of BAY3563254. They will take BAY3563254 as an injection into a vein. All participants in the second part of the study, called dose expansion, will receive the most appropriate dose of BAY3563254 that was identified from the first part of the study. Participants in this study will take the study treatment once every 6 weeks, which is known as a treatment cycle. Each participant will have up to 4 of these treatment cycles, if the participant benefits from the treatment. Each participant will be in the study for approximately 6 years, including a screening phase of up to 30 days, 6 months of treatment depending on the participant's benefit, and a follow up phase of 60 months after the end of treatment. In addition, substudies performed during both dose escalation and dose expansion parts of the study will evaluate: * the clearance of radioactivity from the body over time * the doses of radiation that are delivered to normal organs and tumors During the study, the doctors and their study team will: * take blood and urine samples * check vital signs such as blood pressure, heart rate, and body temperature * examine heart health using electrocardiogram (ECG) * take tumor samples if required * check if the participants' cancer has grown and/or spread using CT (computed tomography) or MRI (magnetic resonance imaging) and bone scan * check the tumor status using PET (positron emission tomography) * check the amount of radiation absorbed by tumors and normal organs using SPECT/CT (single-photon emission tomography and computed tomography scan) * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study. The treatment period ends with a visit in 6-12 weeks after the last BAY3563254 dose. About 6-12 weeks after the last dose and every 6 weeks thereafter, the study doctors and their team will check the participants' health and any changes in their cancer. This active follow-up period ends after 18 months. The long-term follow-up period will start after the end of the active follow-up visit and will continue for up to 60 months after the the last BAY3563254 dose. Participants will be contacted, typically by phone call or clinic visit, approximately every 12 weeks after the end of active follow-up.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:PSMA-negative Lesions, Recent Anticancer Therapy, Others
      Must Be Taking:LHRH, GnRH

      235 Participants Needed

      BAY3546828 for Prostate Cancer

      Houston, Texas
      Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new treatment options for participant(s) with prostate cancer in recent years, the cancer often returns and worsens. The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for participants with mCRPC who have already received available treatments or have few treatment options available. It works by binding to a protein on the surface of the cancer cells called prostate specific membrane antigen (PSMA). As it gives off a type of radioactivity that travels a very short distance, it kills the nearby (cancer) cells that express PSMA. The main purpose of this first-in-human study in participants with mCRPC is to learn: * How safe different doses of 225Ac-pelgi are. * To what degree medical problems caused by 225Ac-pelgi can be tolerated by the participants? * Which dose of 225Ac-pelgi is optimal for treatment (safe and working well)? * How good is 225Ac-pelgi's anticancer activity? To answer this, the researchers will look at: * The number and severity of medical problems that the participants have after treatment with 225Ac-pelgi (per dose level). * The ratio of medical problems and anticancer activity per dose. * Anticancer activity of the optimal 225Ac-pelgi dose as proportion of participants who have at least halved prostate-specific antigen (PSA) levels after 12 weeks of treatment or later and/or shrunken or no longer detectable tumors. * The lowest PSA level reached after treatment start. Doctors keep track of all medical problems (also called adverse events) that participants have during the study, even if they do not think that they might be related to the study treatment. Anticancer activity is measured using cancer imaging techniques and change in blood level of a protein called PSA. PSA is made by normal and by cancerous cells in the body. The PSA level is taken as a marker for prostate cancer development and is usually elevated in participants with mCRPC. In addition, researchers want to find out how 225Ac-pelgi moves into, through and out of the body. The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose and schedule that can be given in the second part of the study. For this, each participant will receive one of the predefined increasing doses of 225Ac-pelgi as an infusion into the vein. All participants in part 2, called dose expansion, will receive the most appropriate dose and schedule identified from the first part of the study. More than one dose level or schedule from part 1 may be tested. Both the participants and the study team know what treatment the participants will take. Participants in this study will take the study treatment 225Ac-pelgi once in a period of 6 weeks called a cycle. Each participant will have 4 of these treatment cycles, if the participant benefits from the treatment. Each participant will be in the study for up to nearly six years, including a first test (screening) phase of a maximum of 30 days, up to 12 months of treatment depending on the participant's benefit, and a follow-up phase of 60 months after the end of treatment. The following visits to the study site are planned: 2 during the screening phase, 8 in the first treatment cycle, 7 in subsequent cycles, and a visit 6 to 12 weeks after the last dose. In the following 12 months, visits are planned every 6 weeks and during the next 48 months phone calls or clinic visits are planned approximately every 12 weeks. In addition, a sub study during the dose escalation part will gather information on the distribution of the study treatment in the body, the proportion that binds to the cancer cells, and the resulting radiation at the tumor site. During the study, the study team will: * Do physical examinations * Check vital signs such as blood pressure, heart rate, and body temperature * Take blood, and urine samples * Examine heart health using echocardiogram and electrocardiogram (ECG) * Take tumor samples * Track 225Ac-pelgi in the body using gamma imaging (generally available at all study sites) * Check the tumor status using PET (positron emission tomography), CT (computed tomography) or MRI (magnetic resonance imaging) and bone scan * Ask questions about the impact of the disease on the participants' wellbeing and activities of daily life (Eastern Cooperative Oncology Group Performance status (ECOG PS)).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Psma-negative Lesions, Recent Anticancer Therapy, Others
      Must Be Taking:Novel Androgen Axis Drugs

      232 Participants Needed

      Dietary Intervention for Prostate Cancer

      Houston, Texas
      This clinical trial studies the effects of a dietary intervention prior to surgery (neoadjuvant) in patients with intermediate risk prostate cancer. Changing your diet before surgery may help to improve overall health. Information from this study may help researchers better understand the influence of diet on the outcomes of patients with intermediate prostate cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:30 - 75
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Dietary Restrictions, Smoking, Heavy Drinking, Others

      12 Participants Needed

      Lifestyle Intervention for Prostate Cancer Quality of Life

      Houston, Texas
      This pilot trial studies how well Watchful Living works in improving quality of life in participants with prostate cancer that has not spread to other parts of the body who are on active surveillance and their partners. A social support lifestyle intervention (called Watchful Living) may help African American prostate cancer participants and their partners improve their quality of life, physical activity, diet, and inflammation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Noncutaneous Malignancy, Prior Radiation, Others
      Must Not Be Taking:Immunotherapy, Hormonal Therapy, Chemotherapy

      64 Participants Needed

      Lu-177 PSMA for Prostate Cancer

      Houston, Texas
      To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Women, Children, Others
      Must Be Taking:Pluvicto

      25 Participants Needed

      Water Vapor Ablation for Prostate Cancer

      Houston, Texas
      This trial is testing a device called Vanquish that uses steam to treat prostate cancer. It targets men with a specific type of intermediate-risk prostate cancer. The steam heats up and kills the cancer cells in the prostate.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50+
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:GGG3 Cores, MRI ECE, PI-RADS 5, Others
      Must Not Be Taking:Hormonal Prostate Medications

      400 Participants Needed

      Advanced MRI Techniques for Prostate Cancer

      Houston, Texas
      This clinical trial studies examines a 3D magnetic resonance imaging (MRI) compared to standard MRI imaging techniques in screening patients with prostate cancer. Diagnostic procedures, such as MRI, may help find and diagnose prostate cancer. Computer systems that allow doctors to create a 3-dimensional (3-D) picture of the tumor may help in planning.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Low-risk Prostate Cancer, Other Malignancy, Cardiac Pacemaker, Others

      33 Participants Needed

      mpMRI with Flexible AIR Coil for Prostate Cancer

      Houston, Texas
      Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group \<2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. Many investigators, including our group, have shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for surgical planning.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Low-risk Adenocarcinoma, Other Active Malignancy, Others

      258 Participants Needed

      MRI for Prostate Cancer

      Houston, Texas
      This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Claustrophobia, Metallic Objects, Renal Failure, Others

      852 Participants Needed

      Social Determinants Study for Prostate Cancer

      Houston, Texas
      This trial is aimed to better understand the impact of migration history on the quality of life of Black immigrant CaP survivors (both SSAI and CI). We will illuminate the full range of racial, social, environmental, behavioral, and structural factors associated with the Black immigrant experience in the US using a SDOH model.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Sex:Male

      40 Participants Needed

      Mediterranean Diet for Prostate Cancer

      Houston, Texas
      This study, we will build upon our prior work and test the feasibility of a Mediterranean diet intervention for medically underserved men with prostate cancer seen at LBJ Hospital, a large safety net facility in Harris County, TX.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Special Dietary Needs, Unwillingness, Inability To Keep Appointments, Nuts Allergy

      25 Participants Needed

      SpaceIT Hydrogel System for Prostate Cancer

      Houston, Texas
      To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Other Cancers, Others

      230 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54
      Match to a Prostate Cancer Trial

      ORGOVYX for Prostate Cancer

      Houston, Texas
      This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Surgical Castration, Medical Condition, Others
      Must Be Taking:Orgovyx

      999 Participants Needed

      Cryoablation + SBRT for Bone Metastasis Pain

      Houston, Texas
      This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metastases). Bone is a common site of metastasis in advanced cancer, and bone metastases often result in debilitating cancer-related pain. The current standard of care to treat painful bone metastases is radiation therapy alone. However, many patients do not get adequate pain relief from radiation therapy alone. Another type of therapy that may be used to provide pain relief from bone metastases is cryoablation. Cryoablation is a procedure in which special needles are inserted into the tumor site. These needles grow ice balls at their tips to freeze and kill cancer cells. The goal of this trial is to compare how well cryoablation in combination with radiation therapy works to radiation therapy alone when given to cancer patients to provide pain relief from bone metastases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Cardiac Arrhythmia, Others
      Must Not Be Taking:Antiplatelets, Anticoagulants

      40 Participants Needed

      Lifestyle Changes for Prostate Cancer

      Houston, Texas
      This trial studies how well a lifestyle intervention works in reducing prostate cancer disparities among African American prostate cancer patients and their spouses or romantic partners. A lifestyle intervention may help researchers learn if social support can help African American prostate cancer patients and their partners improve their quality of life, support from their partner, physical activity, diet, and inflammation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Metastatic Cancer, Active Malignancy, Others
      Must Not Be Taking:Immunotherapy, Hormonal Therapy, Chemotherapy, Radiation

      6 Participants Needed

      Proton Therapy vs. Photon Radiation for Prostate Cancer

      Houston, Texas
      This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes \[quality of life (QOL), toxicity, and disease control\] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:30 - 85
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Very High-risk Cancer, Prior Prostate Procedures, Invasive Pelvic Malignancy, Others

      3000 Participants Needed

      MRI Scans for Prostate Cancer

      Houston, Texas
      This trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer. Diagnostic procedures, such as magnetic resonance whole body diffusion-weighted imaging (a method to show how water moves in a certain area) may help find bone or lymph nodes metastasis.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Low Metastasis Risk, MRI Contraindication, Others
      Must Not Be Taking:Testosterone Suppressants

      98 Participants Needed

      Barrigel for Prostate Cancer

      Houston, Texas
      Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Allergy To Hyaluronic Acid, Others
      Must Not Be Taking:Steroids

      84 Participants Needed

      Immunotherapy for Prostate Cancer

      Houston, Texas
      This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      144 Participants Needed

      XB002 for Advanced Cancers

      Houston, Texas
      This trial is testing a new drug called XB002, given through an IV periodically, to see if it can help patients with advanced solid tumors. The drug is tested alone and with other cancer treatments. Researchers are checking if it is safe and effective in shrinking or stopping tumor growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      573 Participants Needed

      Relugolix vs Leuprolide for Prostate Cancer

      Houston, Texas
      This trial compared the safety and heart-related risks of two hormone-lowering medications, relugolix and leuprolide acetate, in adults with prostate cancer. These drugs help manage cancer by reducing testosterone levels. The study was discontinued, but patients can continue their treatment for a certain period. Relugolix is the first oral medication of its kind and was approved by the FDA based on previous study results.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      2250 Participants Needed

      Nivolumab + Ipilimumab for Prostate Cancer

      Houston, Texas
      The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      351 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Prostate Cancer clinical trials in Houston, TX pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Prostate Cancer clinical trials in Houston, TX work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Prostate Cancer trials in Houston, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Houston, TX for Prostate Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Houston, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Prostate Cancer medical study in Houston, TX?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Prostate Cancer clinical trials in Houston, TX?

      Most recently, we added Abbreviated Biparametric MRI for Prostate Cancer, Family-Centered Lifestyle Intervention for Prostate Cancer Survivors and Lu-177 PSMA for Prostate Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Texas

      Anxiety Clinical Trials in Texas

      Schizophrenia Clinical Trials in Texas

      ADHD Clinical Trials in Texas

      Bipolar Disorder Clinical Trials in Texas

      Multiple Sclerosis Clinical Trials in Texas

      Autism Clinical Trials in Texas

      Treatment Resistant Depression Clinical Trials in Texas

      Borderline Personality Disorder Clinical Trials in Texas

      Social Anxiety Disorder Clinical Trials in Texas

      Parkinson's Disease Clinical Trials in Texas

      Alzheimer's Disease Clinical Trials in Texas

      By Location

      Clinical Trials near Houston, TX

      Clinical Trials near Dallas, TX

      Clinical Trials near San Antonio, TX

      Clinical Trials near Austin, TX

      Clinical Trials near Fort Worth, TX

      Clinical Trials near Plano, TX

      Clinical Trials near Tyler, TX

      Clinical Trials near El Paso, TX

      Clinical Trials near Lubbock, TX

      Clinical Trials near Galveston, TX

      Clinical Trials near Temple, TX

      Clinical Trials near Arlington, TX

      Other People Viewed

      By Subject

      Top Lung Cancer Clinical Trials near Houston, TX

      Top Colorectal Cancer Clinical Trials near Houston, TX

      Top Breast Cancer Clinical Trials near Houston, TX

      Top Prostate Cancer Clinical Trials near Dallas, TX

      Top Clinical Trials near Houston, TX

      Top Diabetes Clinical Trials near Houston, TX

      Top Weight Loss Clinical Trials near Houston, TX

      Top Prostate Cancer Clinical Trials near Austin, TX

      Top Prostate Cancer Clinical Trials near San Antonio, TX

      Top Depression Clinical Trials near Houston, TX

      Top Alzheimer's Disease Clinical Trials near Houston, TX

      Top Prostate Cancer Clinical Trials near Kansas City, MO

      By Trial

      Exercise for Prostate Cancer

      Flibanserin for Prostate Cancer

      HDR Brachytherapy for Prostate Cancer

      mpMRI Monitoring for Prostate Cancer

      Radium-223 + Hormone Therapy + SBRT for Metastatic Prostate Cancer

      Enzalutamide for Prostate Cancer

      HDR Brachytherapy for Recurrent Prostate Cancer

      Abiraterone + Niclosamide + Prednisone for Prostate Cancer

      Poly-ICLC for Prostate Cancer

      Chemoimmunotherapy for Prostate Cancer

      MR/TRUS Fusion Guided Biopsy for Prostate Cancer

      Chemoimmunotherapy + Hormone Therapy for Prostate Cancer

      Related Searches

      Top Prostate-cancer Clinical Trials near Cincinnati, OH

      Top Prostate-cancer Clinical Trials near Kansas City, MO

      Top Prostate-cancer Clinical Trials near Philadelphia, PA

      Top Prostate-cancer Clinical Trials near Phoenix, AZ

      Top Prostate-cancer Clinical Trials near Raleigh, NC

      Top Pediatric-asthma Clinical Trials

      Top Celiac-disease Clinical Trials near Tampa, FL

      Top Mental-health Clinical Trials

      Tourniquet Use for Anterior Cruciate Ligament Repair

      Paravertebral Block for Postoperative Pain

      Super-Oxygenated Water for Volunteers

      ProCell Wrung for Blood Transfusion